OGA and tauopathy: O-GlcNAcase inhibitors are currently in clinical trials for tauopathies (Selnick et al., 2019), and therefore it will be important to know whether these drugs might affect α-synuclein functions and dysfunctions at synapses in order to ward off any undesirable effects.